Abstract:Background Accelerated approval (AA) of novel anticancer drugs based on surrogacy has attracted considerable concern globally. China National Medical Products Administration (NMPA) also established a similar conditional approval (CA) program to accelerate the approval of novel drugs to address unmet medical needs. This cross-sectional study aimed to evaluate the pre-approval clinical trial evidence and potential challenge of cancer drugs receiving CA in China from policy implementation to 2022. Methods The cancer drugs (initial and supplemental indications) granted CA between January 1, 2015 and December 31, 2022 using the public database of the NMPA were analyzed. The characteristics of the cancer drugs received CA were described. Primary efficacy endpoints and safety derived from the pre-approval clinical trial, including response rates (RR), progression-free survival (PFS), overall survival (OS), treatment-related serious adverse events (SAE) and Grade >= 3 adverse events (AEs) were quantitatively estimated by meta-analysis. Besides, the correlation between the surrogate endpoints and OS was estimated by the reported trial-level correlation analysis. Findings The NMPA approved 72 cancer indications (56 new molecular entities) with CA between 2015 and 2022.34 indications (47%) were also approved by the FDA or EMA. 74% (53/72) of cancer indications were based on a single-arm trial design while 26% (19/72) for randomized controlled trials. The pooled RR was 0.50 (95% CI: 0.45-0.55, I-2 = 96%) with significant differences across cancer types and targets while the pooled hazard risk was 0.39 (95% CI: 0.28-0.53, I-2 = 89%) for PFS and 0.67 (95% CI: 0.61-0.73, I-2 = 0%) for OS. The pooled treatment-related SAE and Grade >= 3 AEs from single-arm designs resulted in 15% and 25%, respectively. In randomized controlled trials, the pooled treatment-related SAE and Grade >= 3 AEs observed in CA drugs and the control groups were comparable. Surrogate endpoints were widely used as the primary efficacy endpoints in the pre-approval pivotal clinical trials with 75% (54/72) for RR, 10% (7/72) for PFS, and 4% (3/72) for others. Of these, 27% (17/63) of the surrogate endpoints reported a trial-level correlation with OS; three reported high correlation (r >= 0.85), two reported moderate correlation (0.70 <= r < 0.85) and 12 reported low correlation (r < 0.70). Interpretation The majority of novel cancer drugs that received CA were based on RR designed for single-arm trials. The reported correlations of treatment effect between the surrogate endpoints and OS used for CA were limited. Our findings highlighted that the introduction of OS or quality of life based on RCT in confirmatory clinical trials as much as feasible was essential to ensure the clinical benefits for patients. Copyright (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution

Limited and uneven geriatric cancer drug trials worldwide.

Research Progress of Treatments on Colorectal Cancer in Elderly Patients

Geriatric drug trials on solid tumor are scarce worldwide

Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review

Acceptance and Related Causes of Clinical Trials among Cancer Patients in China

Assessment of Clinical Trial Evidence and Surrogate Endpoints Strength for the Cancer Drugs Granted Conditional Approval in China

A Call for Innovative Translational and Clinical Research to Address China's Unique Cancer Landscape

Targeting rare tumors: new focus for clinical research in China.

The current status of clinical trials on cancer and age disparities among the most common cancer trial participants

Evidence of Pre-Approval Clinical Trial Supporting the Granted Conditional Approval for Novel Cancer Drugs in China Between 2015 and 2022.

Accelerating the integration of China into the global development of innovative anticancer drugs

Access to cancer clinical trials for racialised older adults: an equity-focused rapid scoping review protocol

[Awareness and Influencing Factors of Clinical Trial among Cancer Patients in China].

Refusal of treatment among HER2-positive breast cancer patients in China: a retrospective analysis

Navigating the Path to Inclusion: Understanding Barriers and Facilitators to Clinical Trial Participation Among Chinese Older Adults in the United States with Multimorbidity

Overall Survival Benefits of Cancer Drugs Approved in China from 2005 to 2020

Cancer Drug Indication Approvals in China and the United States: a Comparison of Approval Times and Clinical Benefit, 2001–2020

Challenges in Anticancer Drug R&D in China

Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020

Growing research and development of targeted anticancer drugs in China